2006-03-012024-05-17https://scholars.lib.ntu.edu.tw/handle/123456789/682569摘要：第二型豬環狀病毒 (PCV2) 已被證實為引起豬離乳後多系統消耗性症候群(PMWS)的主要致病因子，為一重要的豬隻新興疾病，在世界各養豬國家均造成感染，導致重大的經濟損失。由於PCV2為一極為穩定且對環境抵抗力強的病毒，因此豬隻一旦遭受本病毒感染後，不易被清除，養豬場因而會長期的帶有本病毒，並散播感染其他的豬隻。為能有效的防控本病以減少經濟上的損失，研發合乎經濟效益的強有力疫苗為一重要措施。應用基因工程技術產製具中和效力及/或激發細胞性免疫力的次單位疫苗，為一可大量生產、合乎經濟效力的選擇。本計畫為配合PCV2次單位疫苗研發及應用的臨床前檢測試驗研究，其目的在進行最終的PCV2次單位疫苗疫苗效力評估或動物攻毒實驗之前，建立對單一或多種不同的PCV2次單位疫苗疫苗抗原蛋白之免疫效力評估方法，以利未來疫苗免疫效力之檢測。<br> Abstract: Porcine circovirus type 2 has been demonstrated to be the major factor for inducing postweaning multisystemic wasting syndrome (PMWS) in pigs, although the presence of other co-factors are necessary. This disease has become a new emerging disease and caused significant impact on pig production worldwide. Because of the strong stability and environmental resistance of PCV2, it is not easy to clean this virus from the farm once infected; this also makes the affected farm carry this virus for a long period of time and continuously spread to the newly introduced pigs. In order to control this disease more effectively and to reduce the economic loss, development of good and less cost vaccine has become an important task. The use of genetic engineering techniques to produce a subunit vaccine that is capable of effectively inducing virus neutralizing antibody and/or specific cell-mediated immunities seems to be a choice for the purpose of less cost and large scale production. The objective of the present study is to establish the methodologies that could be used for testing the humoral and cell-mediated immunogenecity of the developing PCV2 subunit vaccine before its preclinical trial.第二型豬環狀病毒次單位疫苗免疫效力porcine circovirus type 2subunit vaccineimmunogenicity